Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02382666 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers
A Phase 1 study, sponsored by Tesaro.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT02382666 is a Phase 1 study that has completed, run by Tesaro. The registered enrollment target is 100 participants.
The verdict
NCT02382666, a Phase 1 study, has completed, sponsored by Tesaro.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of single increasing doses of intravenously administered rolapitant in healthy male and female subjects.
Interventions
- DRUG Rolapitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02382666
The ClinicalTrials.gov registry entry for NCT02382666 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tesaro, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rolapitant is the first listed.
NCT02382666 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02382666 about?
NCT02382666 is a clinical study titled "A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers". The purpose of this study is to assess the safety and tolerability of single increasing doses of intravenously administered rolapitant in healthy male and female subjects.
What is the current status of trial NCT02382666?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2015-01. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02382666?
The interventions under investigation include: Rolapitant (DRUG).
Who is sponsoring clinical trial NCT02382666?
This trial is sponsored by Tesaro, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.